R.H. Bluestein & Co’s Nektar Therapeutics NKTR Stock Holding History

R.H. Bluestein & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-180	Closed	-$287K	–	325
2018 Q1	$287K	Buy	+180	New	+$232K	0.02%	256

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

R.H. Bluestein & Co's NKTR Position: Q2 2018 in Review

R.H. Bluestein & Co sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 180 shares — an estimated $287K sold.

R.H. Bluestein & Co first reported a position in NKTR in Q1 2018 and held it in 1 quarter. The position peaked at $287K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

R.H. Bluestein & Co reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
R.H. Bluestein & Co sold 180 Nektar Therapeutics shares in Q2 2018, an estimated $287K.
R.H. Bluestein & Co first reported a position in Nektar Therapeutics in Q1 2018 and held it in 1 quarter.
R.H. Bluestein & Co's Nektar Therapeutics position peaked at $287K in Q1 2018.
379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on R.H. Bluestein & Co's 13F filing for Q2 2018, filed 10 Aug 2018.